We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MIAX:NYSEMiami International Holdings, Inc. Analysis

Data as of 2026-05-19 - not real-time

$54.51

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Miami International Holdings (MIAX) is trading at $54.51, comfortably above its 20‑day SMA ($49.40) and well above the 50‑day ($44.10) and 200‑day ($42.49) averages, indicating strong bullish momentum. Technicals reinforce this view: the RSI sits at 73 (overbought but still supportive of upward pressure), the MACD line ($3.24) is above its signal ($2.65) and the histogram is positive, and the trend is flagged as bullish with increasing volume. However, the stock is near its resistance level of $57.14 and its DCF‑derived fair value of $38.84 suggests it is currently overvalued, with a downside potential of about 6%.
Fundamentally, MIAX posted 13% revenue growth, solid cash reserves ($596 M) and minimal debt ($22.7 M), delivering a 12.4% operating margin and an 8.6% profit margin. Analysts are optimistic, assigning a “Buy” rating and a Zacks Rank 2 upgrade, while the market sentiment is in “Extreme Greed” (Fear‑Greed Index 89). Yet the forward PE of 29.9 versus an industry average of 16.7 underscores a premium valuation. The combination of robust short‑term technicals, strong balance sheet, but elevated valuation and high short‑term volatility (≈31% 30‑day) frames a nuanced outlook.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish technical indicators (price above all SMAs, MACD bullish)
  • RSI in overbought territory near resistance at $57.14
  • Increasing volume supporting current trend

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong revenue growth (13%) and solid cash position
  • Analyst upgrades and Zacks Rank 2 Buy
  • Valuation premium (PE 42 vs industry 16) limiting upside

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • DCF fair value ($38.84) well below current price
  • High forward PE (29.9) indicating limited long‑run upside
  • Potential regulatory headwinds in capital‑markets segment

Key Metrics & Analysis

Financial Health

Revenue Growth13.00%
Profit Margin8.64%
P/E Ratio42.3
ROE16.83%
ROA7.03%
Debt/Equity2.13
P/B Ratio4.8
Op. Cash Flow$217.5M
Free Cash Flow$139.3M
Industry P/E16.7

Technical Analysis

TrendBullish
RSI73.0
Support$43.96
Resistance$57.14
MA 20$49.40
MA 50$44.10
MA 200$42.49
MACDBullish
VolumeIncreasing
Fear & Greed Index89.25

Valuation

Fair Value$38.84
Target Price$51.20
Upside/Downside-6.07%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.70
Volatility30.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.